Alivus Life Sciences Limited (NSE: ALIVUS) announced its financial results for the second quarter and half-year ended September 30, 2026, showcasing a robust performance. Revenue from operations for Q2FY27 came at Rs. 6,820 Mn, marking a 16.0% year-over-year growth, driven by broad-based momentum in the non-GPL business which grew at 20.8% YoY. EBITDA for Q2FY27 stood at Rs. 2,851 Mn, a growth of 47.0% YoY with margins at 41.8%, up 520 bps QoQ & 880 bps YoY, driven by favourable product mix, new launches, and the benefits of operating leverage.

Strong Financial Performance

The company generated a strong free cash flow of Rs. 2,702 Mn, leading to Cash and Cash Equivalents (including short-term investments) of Rs. 10,116 Mn as of September 30, 2026. Commenting on the company’s performance Dr. Yasir Rawjee, MD & CEO, Alivus Life Sciences Limited said, “Q2FY27 was another strong quarter for us, with revenue growing 16.0% YoY, supported by healthy demand across all key markets and robust contributions from recent launches. Non-GPL business momentum was maintained, while CDMO business saw a meaningful pick-up during the quarter. The improving business mix and greater operating efficiencies also translated into better underlying profitability. Looking ahead, our ongoing capacity expansion and healthy development pipeline give us confidence in sustaining this momentum and delivering consistent growth.”

Future Outlook

Tushar Mistry, CFO, Alivus Life Sciences Limited said, “We delivered a strong financial performance in Q2FY27, with healthy revenue growth, improved profitability and robust cash generation. Revenue grew 16.0% YoY, supported by a favourable product mix. Healthy operating performance translated into strong cash generation, with cash flow from operations of Rs. 270 crores during H1FY27. With cash and cash equivalents of Rs. 1,012 crores as of September 30, 2026, we have ample financial flexibility to support our growth initiatives while maintaining a healthy, debt-free balance sheet. Going forward, we remain focused on sustaining profitable growth, maintaining financial discipline and creating long-term value.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Alivus Life Sciences Limited

Alivus Life Sciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Alivus gains 15.6% over three months and trades near its 52-week highs. The PEG stands at 4.11 — severely stretched. Any earnings miss could trigger a sharp de-rating. Margins at 23.3% are impressive but need to be sustained — any compression would be a red flag. The stock gives back 4.5% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The stock rises 15.6% in three months on 6.9% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Alivus Life Sciences Limited.

Alivus Life Sciences Limited (NSE: ALIVUS) announced the acquisition of a 76% stake in IQGenX Pharma Private Limited for INR 91.2 million. This strategic move aims to leverage IQGenX’s expertise in advanced formulation development, enhancing Alivus’s capabilities in oral solids, sterile injectables, and ophthalmic solutions. The acquisition will enable Alivus to expand its global customer base in the generic pharmaceutical segment.

Enhanced Formulation Development

IQGenX, founded in 2016, specializes in formulation development for highly regulated markets. This acquisition will allow Alivus to integrate end-to-end platforms offering deep scientific expertise across complex delivery formats. Alivus will now provide rigorous bioequivalence and stability studies, enabling comprehensive regulatory filings for diverse global markets.

Expanded Service Platform

The expanded service platform will cover pre-formulation studies, prototype development, process optimization, clinical supplies, and full-scale commercial manufacturing. Additionally, analytical development, methods validation, stability programs, and complete regulatory submission support will be offered. This will significantly scale up Alivus’s value proposition for global CDMO customers.

Alivus will strategically leverage IQGenX’s specialized platform alongside its own world-class API portfolio, focusing on oncology to curate a high-impact basket of differentiated, niche assets. These assets, backed by validated commercial-scale manufacturing capabilities, are primed for strategic out-licensing across multiple geographies.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Alivus Life Sciences Limited

Alivus Life Sciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Alivus gains 32.8% over three months and trades near its 52-week highs. The PEG stands at 4.35 — severely stretched. Any earnings miss could trigger a sharp de-rating. Margins at 23.3% are impressive but need to be sustained — any compression would be a red flag. RSI hits 74, a level that signals the stock runs hot. Notably, buyers drove volume on 15 recent sessions — though at these levels, some profit-taking is normal. The stock rises 32.8% in three months on 7.6% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Alivus Life Sciences Limited.

Alivus Life Sciences Limited (ALIVUS) breaks out, gaining +10% to ₹1342.9 on the NSE on 04 Aug 2026. This move is driven by the stock clearing its 6M resistance trendline, transitioning from a breakdown to a breakout. Alivus operates in the specialty and generic drug manufacturing segment within the healthcare sector. Today’s move appears to be company-specific, driven by technical factors rather than broader sector momentum.

Technical setup — trendlines & DMA

Currently, Alivus is trading above its 6M support trendline at ₹1176.5, which is 12.39% below today’s price, and has broken through its 6M resistance trendline at ₹1205.83, now 10.21% above it. The stock is also 10.49% above its 50-DMA at ₹1099.1 and 23.23% above its 200-DMA at ₹985.5, indicating a stretched move. Within its 52W range of ₹819.0–₹1225.0, the stock is in the upper third, suggesting that much of the recent momentum is already priced in.

Fundamentals & business context

With a PE of 24.7 and profit margins at 23.3%, Alivus’s valuation appears to be reflecting its solid earnings quality. However, the revenue CAGR of 7.6% and profit CAGR of 6.5% over the past five years suggest that the stock’s price may be somewhat stretched relative to its growth rate. The 8.9% institutional ownership indicates a cautious approach by smart money, possibly due to the stock’s overvalued PEG ratio of 3.80. There is no NSE catalyst today, making this move primarily technical.

Algorithmic scorecard

The overall algorithmic scorecard indicates a technically strong but fundamentally weaker profile. The strongest signals are the bullish trend, with the 50-DMA above the 200-DMA, and the bullish sentiment over the last 30 days, where volume on up days has been 1.31x higher than on down days. These signals suggest systematic accumulation and positive momentum. However, the weakest signals are the overvalued PEG ratio and the negligible dividend yield, which represent risks of overpricing and lack of income generation, respectively.

Company outlook

Management outlined several key forward-looking metrics and strategic initiatives. They expect to sustain EBITDA margins between 30% to 32% going forward and plan a capex of about INR 540 crores for FY27, funded through internal accruals. Capacity utilization in brownfield is expected to reach 80-90% in 2 to 3 quarters, while Solapur is projected to start with 40-50% utilization, increasing to 60-70% the following year. The CDMO business is expected to see continued momentum with new deals on the horizon. A significant revenue jump is anticipated in FY28 as capex comes online. Strategic priorities have shifted towards lateral growth and higher entry barriers to sustain profitability, with an even distribution of revenue across mature geographies and a growing presence in Japan. Capacity expansion is planned from 1,198 KL in FY24 to 2,690 KL by FY28, and R&D spend is expected to settle around 4% of sales in the next 2 to 3 years. The company also hopes to close 2 new CDMO deals in the early second half of the current year.

Get all details on ALIVUS — P&L, peers, shareholding and more on TradeAlone.